This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Symlin and Metreleptin
Takeda Pharmaceutical Company Ltd
Drug Names(s): AC137-164594, Recombinant-methionyl (r-met) human leptin / r-metHuLeptin / AC164594 plus pramlintide / AC137
Description: BioMedTracker has separate drug profiles for the Symlin and Symlin in combination with leptin. Please also see Symlin.
Leptin is a naturally occurring protein hormone secreted by fat cells. It plays a key role in metabolism through multiple metabolic actions and appears to act primarily at the hypothalamus to regulate food intake and energy expenditure.
Symlin is an amylin analog. Amylin is a hormone secreted with insulin by pancreatic b cells. Its physiologic effects include augmenting insulin action at multiple levels of metabolism including glucose control and other aspects of energy utilization. Preclinical investigation discovered amylin acts as a neuroendocrine hormone that complements insulin effects in postprandial glucose regulation by suppressing postprandial glucagon secretion and slowing the rate of nutrient delivery from the stomach to the small intestine.
Amylin and/or its effects can be missing or diminished in diabetes mellitus, much in the same way that insulin or insulin sensitivity is lost. Human amylin is not optimal for replacement therapy for various biochemical reasons. Therefore, pramlintide, a soluble, nonaggregating synthetic peptide analog of human amylin, was developed. Pramlintide, the active ingredient of Symlin, has potency at least equal to that of human amylin.
Amylin and Amgen
In early 2006, Amylin acquired the exclusive rights to the leptin molecular franchise and program from Amgen. Under the terms of the license agreement, Amylin made an up-front payment, may make potential future payments related to technology transfer and development and regulatory milestones and will pay royalties on any product sales. Amylin's license includes exclusive rights to the leptin intellectual property developed by Amgen as well as intellectual property Amgen originally licensed from Rockefeller University.
Amylin and Takeda
In November 2009, Amylin Pharmaceuticals and Takeda Pharmaceutical announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide. The...See full deal structure in Biomedtracker
Partners: Amgen, Inc. Bristol-Myers Squibb Company
Symlin and Metreleptin News
Additional information available to subscribers only: